Linaclotide in constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: a profile of its use in the USA

被引:0
|
作者
McKeage K. [1 ]
Lyseng-Williamson K.A. [1 ]
机构
[1] Springer, Private Bag 65901, Mairangi Bay, Auckland
关键词
D O I
10.1007/s40267-017-0448-0
中图分类号
学科分类号
摘要
Linaclotide (Linzess®) is a synthetic guanylate cyclase C agonist that acts locally in the gastrointestinal tract to increase intestinal fluid levels, increase colonic transit, and reduce peripheral pain. In adults with constipation-predominant irritable bowel syndrome (IBS-C) or chronic idiopathic constipation (CIC), once-daily oral linaclotide 290 µg (IBS-C), or 145 or 72 µg (CIC), significantly improved stool frequency and consistency, abdominal pain and bloating, and health-related quality-of-life. Linaclotide is generally well tolerated and, consistent with its therapeutic action, diarrhea is the most common adverse event. © 2017, Springer International Publishing AG.
引用
收藏
页码:497 / 504
页数:7
相关论文
共 50 条
  • [41] Linaclotide: A novel agent for chronic constipation and irritable bowel syndrome
    Love, Bryan L.
    Johnson, Audrey
    Smith, Lisa S.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (13) : 1081 - 1091
  • [42] Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation
    Abrahamsson, Hasse
    Ostlund-Lindqvist, Ann-Margret
    Nilsson, Ralf
    Simren, Magnus
    Gillberg, Per-Goran
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2008, 43 (12) : 1483 - 1488
  • [43] Constipation and Constipation-predominant Irritable Bowel Syndrome: A Comparative Study Using Rome III Criteria
    Rajindrajith, Shaman
    Devanarayana, Niranga M.
    Benninga, Marc A.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 64 (05): : 679 - 684
  • [44] Effect of Linaclotide in Improving Quality of Life in Patients with Constipation-predominant Irritable Bowel Syndrome (IBS-C)
    Atluri, Dileep
    Falck-Ytter, Yngve
    Chandar, Apoorva
    Bharucha, Adil
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S566 - S566
  • [45] CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME AND FUNCTIONAL CONSTIPATION ARE NOT DISCRETE DISORDERS: A MACHINE LEARNING APPROACH
    Ruffle, James
    Tinkler, Linda
    Emmett, Christopher
    Ford, Alex
    Nachev, Parashkev
    Aziz, Qasim
    Farmer, Adam
    Yiannakou, Yan
    GUT, 2021, 70 : A218 - A218
  • [46] Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo
    Ziegenhagen, DJ
    Kruis, W
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (07) : 744 - 749
  • [47] White Matter Microstructural Similarity and Diversity of Functional Constipation and Constipation-predominant Irritable Bowel Syndrome
    Nan, Jiaofen
    Zhang, Liangliang
    Chen, Qiqiang
    Zong, Nannan
    Zhang, Peiyong
    Ji, Xing
    Ma, Shaohui
    Zhang, Yuchen
    Huang, Wei
    Du, Zhongzhou
    Xia, Yongquan
    Zhang, Ming
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 24 (01) : 107 - 118
  • [48] Potential effects of sodium hyaluronate on constipation-predominant irritable bowel syndrome
    Cui, Li
    Zou, Shuting
    Liu, Jing
    Lv, Huixia
    Li, Hui
    Zhang, Zhenhai
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
  • [49] Constipation-Predominant Irritable Bowel Syndrome Complicating Asymptomatic Nonrotation of the Midgut
    Plackett, Timothy P.
    Myers, Jonathan
    Gagliano, Ronald A., Jr.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2010, 110 (08): : 437 - 440
  • [50] Colchicine Plus Olsalazine for Treatment of Constipation-Predominant Irritable Bowel Syndrome
    Barody, Thomas J.
    Hills, Lauren A.
    Torres, Margaux
    GASTROENTEROLOGY, 2009, 136 (05) : A484 - A484